A multi-country, multicenter, randomized, open-label, parallel group study to assess the efficacy and safety of Docecal compared with Taxotere

Trial Profile

A multi-country, multicenter, randomized, open-label, parallel group study to assess the efficacy and safety of Docecal compared with Taxotere

Discontinued
Phase of Trial: Phase III

Latest Information Update: 19 May 2017

At a glance

  • Drugs Docetaxel (Primary)
  • Indications Adenocarcinoma; Breast cancer
  • Focus Therapeutic Use
  • Sponsors Oasmia Pharmaceutical
  • Most Recent Events

    • 18 May 2017 Status changed from recruiting to discontinued.
    • 16 Nov 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top